JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB269641

Human CYP1B1 knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

CYP1B1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion, 2 bp deletion; Frameshift: 100%.

View Alternative Names

Aryl hydrocarbon hydroxylase, CP1B, CP1B1_HUMAN, CYPIB1, Cytochrome P450 1B1, Cytochrome P450 family 1 subfamily B polypeptide 1, Cytochrome P450 subfamily I (dioxin inducible) polypeptide 1 (glaucoma 3 primary infantile), GLC3A, Microsomal monooxygenase, P4501B1, Xenobiotic monooxygenase, flavoprotein-linked monooxygenase

2 Images
Western blot - Human CYP1B1 knockout A549 cell lysate (AB269641)
  • WB

Lab

Western blot - Human CYP1B1 knockout A549 cell lysate (AB269641)

Western blot : Anti-CYP1B1 antibody [EPR14972] (ab185954) staining at 1/5000 dilution, shown in black; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab185954 was shown to bind specifically to CYP1B1. A band was observed at 55 kDa in wild-type A549 cell lysates with no signal observed at this size in CYP1B1 knockout cell line ab269476 (knockout cell lysate ab269641). To generate this image, wild-type and CYP1B1 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times before development with a high-sensitivity ECL substrate kit and imaged with 8 minutes exposure time. Secondary antibodies used were HRP conjugated Goat anti-Rabbit (H+L) and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-CYP1B1 antibody [EPR14972] - C-terminal (<a href='/en-us/products/primary-antibodies/cyp1b1-antibody-epr14972-c-terminal-ab185954'>ab185954</a>) at 1/5000 dilution

Lane 1:

Wild-type A549 cell lysate at 20 µg

Lane 2:

CYP1B1 knockout A549 cell lysate at 20 µg

Lane 2:

Western blot - Human CYP1B1 knockout A549 cell lysate (ab269641)

Lane 2:

Western blot - Human CYP1B1 knockout A549 cell line (<a href='/en-us/products/cell-lines/human-cyp1b1-knockout-a549-cell-line-ab269476'>ab269476</a>)

Lane 3:

HeLa cell lysate at 20 µg

Lane 4:

MCF7 cell lysate at 20 µg

Lane 5:

SiHa cell lysate at 20 µg

Lane 6:

Human Brain cell lysate at 20 µg

Lane 7:

Human Kidney cell lysate at 20 µg

Lane 8:

Human Liver cell lysate at 20 µg

Lane 9:

HepG2 cell lysate at 20 µg

Lane 10:

LoVo cell lysate at 20 µg

Secondary

All lanes:

HRP conjugated Goat anti-Rabbit (H+L) and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

Predicted band size: 61 kDa

Observed band size: 55 kDa

false

Next Generation Sequencing - Human CYP1B1 knockout A549 cell lysate (AB269641)
  • NGS

Supplier Data

Next Generation Sequencing - Human CYP1B1 knockout A549 cell lysate (AB269641)

Knockout achieved by CRISPR/Cas9; X = 1 bp insertion, 2 bp deletion; Frameshift : 100%

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Next Generation Sequencing,Western blot

Mutation description

Knockout achieved by CRISPR/Cas9; X = 1 bp insertion, 2 bp deletion; Frameshift: 100%

Disease

Carcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab269641-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB269641-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human CYP1B1 knockout A549 cell lysate", "number":"AB269641-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
CYP1B1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CYP1B1 also known as cytochrome P450 1B1 is a member of the cytochrome P450 superfamily of enzymes. This monoxygenase enzyme with a molecular mass of approximately 60 kDa plays a role in the metabolism of xenobiotics and endogenous compounds. It is mainly expressed in various tissues including the liver lungs and the artery walls. The enzyme catalyzes the hydroxylation of aromatic hydrocarbons aiding in their detoxification and removal from the body.
Biological function summary

CYP1B1 contributes to the metabolism of various drugs and toxins helping to maintain cellular homeostasis. This enzyme also participates in the conversion of steroids and fatty acids impacting hormonal regulation and fatty acid balance. While CYP1B1 does not form a specific complex it functions within the cytochrome P450 enzyme system which collectively metabolizes numerous compounds. This functional integration within a broad enzymatic network highlights its role in chemical transformation processes.

Pathways

CYP1B1 serves an essential role in the Phase I drug metabolism pathway. This pathway includes the functionalization of xenobiotic substances to prepare them for Phase II reactions. The enzyme is involved in the hydroxylation of substrates which are important steps in both the AhR and chemical carcinogenesis pathways. CYP1B1 interacts with other cytochrome P450 family members such as CYP1A1 which further facilitates the detoxification and clearance of harmful compounds from the body.

CYP1B1 is significantly associated with primary congenital glaucoma and various cancers such as breast cancer. In these conditions altered CYP1B1 activity can lead to atypical metabolism of endogenous hormones contributing to disease progression. CYP1B1's interaction with cyclin D1 is noted in cancer pathogenesis where dysregulation of cell cycle progression occurs. Therefore understanding CYP1B1's expression and function can provide insights into therapeutic strategies targeting these disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com